Oncology · AntiemeticRegulatory Approvalregulatorymid-term

FDA Review Status Update for Aprepitant NDA218754 by Azurity

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 12:31:19 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's review of Aprepitant (NDA218754) by Azurity represents a significant development in the oncology antiemetic market. Companies currently competing in this space should closely monitor the review process and prepare for potential shifts in market dynamics following approval. Regulatory context from FDA (FDA AP — APREPITANT (ORIG)) supports the near-term read. Assessment grounded in 28 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape and prepare for potential market entry strategies related to Aprepitant. The strongest clinical anchor is Cognitive Function in Rett Syndrome During Trofinetide Treatment (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Antiemetic, 7 regulatory and 5 competitive items passed relevance filtering for Azurity.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer. This submission indicates Azurity's intent to enter the market with Aprepitant, potentially impacting existing competitors in the antiemetic space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — APREPITANT (ORIG) (FDA). Entity match (azurity); Regulatory pathway relevance (nda). The standard review process indicates a typical timeline for approval, but any delays or issues could affect market entry and competitive positioning.

Key Risks

Elevated medium regulatory exposure for Azurity could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on Azurity through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age) could weigh on Azurity through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If approved, Aprepitant could capture market share from existing antiemetic products, impacting revenue streams for current competitors.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for Azurity may improve if Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the competitive landscape and prepare for potential market entry strategies related to Aprepitant.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any updates on approval status for NDA218754.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — APREPITANT (ORIG)
FDAhigh relevance
Entity match (azurity); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FOSAPREPITANT DIMEGLUMINE (SUPPL)
FDAhigh relevance
Entity match (aprepitant); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FOSAPREPITANT DIMEGLUMINE (SUPPL)
FDAhigh relevance
Entity match (aprepitant); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FOSAPREPITANT DIMEGLUMINE (SUPPL)
FDAhigh relevance
Entity match (aprepitant); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POKONZA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ASk Questions in GYnecologic Oncology (ASQ-GYO)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modeling Host-Pathogen Interaction Using Lymphoid Organoids
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Systematic review with network meta-analysis: efficacy and safety of minimally invasive interventions for symptomatic uterine fibroids.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Azurity
Aprepitant
existing antiemetic competitors

Commercial impact

medium

If approved, Aprepitant could capture market share from existing antiemetic products, impacting revenue streams for current competitors.

Regulatory impact

medium

The standard review process indicates a typical timeline for approval, but any delays or issues could affect market entry and competitive positioning.

What to watch

Monitor the FDA's review timeline and any updates on approval status for NDA218754.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.